ARES heads into its July 31 earnings report having surged 17% in a month, leaving bulls and bears in unusually sharp disagreement about whether the re-rating is justified.
Short sellers have been quietly trimming exposure even as the stock climbed. Short interest rose about 5.5% in a single session on July 24 to reach 7.7% of the free float — roughly 16.7 million shares — but the one-month trend is down nearly 5%. Borrow conditions do nothing to suggest bears are pressing hard: cost to borrow has fallen from around 1.3% in mid-June to just 0.71% now, and availability is comfortable at around 303% of short interest, meaning there are roughly three shares available for every one already borrowed. That's a loose lending market with no squeeze dynamics in play.
Options positioning adds a mild defensive tilt without flashing alarm. The put/call ratio is 1.18, nudging above its 20-day average of 1.15 but only 0.7 standard deviations above it — well short of the kind of elevated hedging that typically signals genuine pre-earnings anxiety. For context, the 52-week peak on the PCR was 3.02, so current readings look measured rather than protective. The stock's 5.4% weekly gain and 1% one-day pop on Monday suggest momentum is firmly in the bulls' hands heading into the print.
The analyst debate captures a real tension in the story. Bulls point to Ares's diversified platform — private credit, digital infrastructure, real assets — as a structural growth engine that merits premium pricing, with a forward EPS expansion rank in the 91st percentile among peers and a strong dividend score. TD Cowen maintains a Buy with a $153 target. But bears flag that private credit as a sector has been de-rating, and several firms trimmed targets in July: Oppenheimer cut to $140 from $146 while keeping Outperform, and Citizens lowered sharply to $160 from $190, though both held positive ratings. Barclays kept Overweight but also nudged its target down to $139. The consensus mean sits at $141, implying roughly 10% upside from current levels — still constructive, but the direction of recent revisions runs against the stock's one-month move.
One institutional angle stands out. Capital Research added nearly 3 million shares in the quarter ended June 30, lifting its stake to 6.6% of shares outstanding. Wellington Management added over 5.3 million shares in the same period, taking a 4.9% position. That's a meaningful accumulation from two major active managers — a signal of conviction that passive flows alone don't explain. Offsetting this, CEO Michael Arougheti and Executive Director Robert DeVeer each sold around 83,000 shares at $111 on June 30 — well below the current price — suggesting at least some insider monetization at levels the market has since moved past. Past earnings prints have been consistently positive: the last three reports all delivered gains on the day, averaging around 3% one-day moves, with five-day returns running even stronger.
The July 31 print will test whether Ares's AUM growth, fee-related earnings, and deployment pace across credit and real assets can validate the sharp re-rating the stock has already priced in — and whether the bear case around private credit sector headwinds has any real bite.
See the live data behind this article on ORTEX.
Open ARES on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
